TG Therapeutics Company Profile (NASDAQ:TGTX)

About TG Therapeutics (NASDAQ:TGTX)

TG Therapeutics logoTG Therapeutics, Inc. (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes. The Company is also developing TGR-1202, an orally available Phosphoinositide 3-kinase (PI3K) delta inhibitor. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies. The Company also has pre-clinical programs focusing on developing interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors and anti- programmed cell death ligand 1 (PD-L1) and anti- glucocorticoid-induced tumor necrosis factor receptor (GITR) antibodies.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Symbol: NASDAQ:TGTX
  • CUSIP: N/A
  • Web: www.tgtherapeutics.com
Capitalization:
  • Market Cap: $524.96 million
  • Outstanding Shares: 62,310,000
Average Prices:
  • 50 Day Moving Avg: $11.95
  • 200 Day Moving Avg: $11.34
  • 52 Week Range: $4.10 - $15.35
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -5.14
  • P/E Growth: 0.000
Sales & Book Value:
  • Annual Revenue: $152,381.00
  • Price / Sales: 3,445.06
  • Book Value: $1.25 per share
  • Price / Book: 6.73
Profitability:
  • EBITDA: ($104,960,000.00)
  • Net Margins: -68,806.59%
  • Return on Equity: -154.02%
  • Return on Assets: -117.88%
Debt:
  • Current Ratio: 4.68%
  • Quick Ratio: 4.68%
Misc:
  • Average Volume: 1.05 million shs.
  • Beta: 1.41
  • Short Ratio: 14.91
 

Frequently Asked Questions for TG Therapeutics (NASDAQ:TGTX)

What is TG Therapeutics' stock symbol?

TG Therapeutics trades on the NASDAQ under the ticker symbol "TGTX."

How were TG Therapeutics' earnings last quarter?

TG Therapeutics, Inc. (NASDAQ:TGTX) announced its quarterly earnings data on Wednesday, August, 9th. The company reported ($0.45) earnings per share for the quarter, beating analysts' consensus estimates of ($0.46) by $0.01. The firm had revenue of $0.04 million for the quarter, compared to analyst estimates of $0.04 million. TG Therapeutics had a negative net margin of 68,806.59% and a negative return on equity of 154.02%. View TG Therapeutics' Earnings History.

Where is TG Therapeutics' stock going? Where will TG Therapeutics' stock price be in 2017?

9 equities research analysts have issued 12 month price objectives for TG Therapeutics' shares. Their forecasts range from $18.00 to $33.00. On average, they anticipate TG Therapeutics' share price to reach $26.75 in the next twelve months. View Analyst Ratings for TG Therapeutics.

What are analysts saying about TG Therapeutics stock?

Here are some recent quotes from research analysts about TG Therapeutics stock:

  • 1. According to Zacks Investment Research, "TG Therapeutics, Inc. is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. The Company is focused on the development of a monoclonal antibody for the treatment of various B-cell proliferative disorders including lymphoma, leukemia, and auto-immune diseases. TG Therapeutics, Inc., formerly known as Manhattan Pharmaceuticals, Inc., is based in New York. " (8/12/2017)
  • 2. FBR & Co analysts commented, "On the morning of March 6, TG Therapeutics announced positive top-line data from its Phase III GENUINE study of TG-1101 (ublituximab) plus ibrutinib in patients with previously treated high-risk chronic lymphocytic leukemia (CLL). The study met its primary endpoint, with an overall response rate (ORR) of 80% in the combination of TG-1101 plus ibrutinib compared to ibrutinib alone in treated patients. The GENUINE Phase III study is a randomized, open-label multi-center trial that is being conducted to evaluate the safety and efficacy of TG-1101 plus ibrutinib compared to ibrutinib alone that has enrolled 126 adult patients with high-risk CLL across 160 clinical sites in the U.S. and Israel. In the study, high risk was defined as patients with one or more of the following: 17p deletion, 11q deletion, or p53 mutation. We believe the top-line data from the study are highly compelling and look forward to the full data set, which the company is targeting to present at a medical meeting in 1H17. The company plans to meet with the FDA to discuss the results and filing for accelerated approval in 2H17." (3/6/2017)

Who are some of TG Therapeutics' key competitors?

Who are TG Therapeutics' key executives?

TG Therapeutics' management team includes the folowing people:

  • Michael S. Weiss, Executive Chairman of the Board, Interim Chief Executive Officer and President
  • Sean A. Power CPA, Chief Financial Officer, Treasurer, Corporate Secretary
  • Kenneth Hoberman, Director
  • Laurence Neil Charney, Independent Director
  • Yann Echelard, Independent Director
  • Neil Herskowitz, Independent Director
  • William J. Kennedy Ph.D., Independent Director

How do I buy TG Therapeutics stock?

Shares of TG Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is TG Therapeutics' stock price today?

One share of TG Therapeutics stock can currently be purchased for approximately $8.43.


MarketBeat Community Rating for TG Therapeutics (NASDAQ TGTX)
Community Ranking:  3.8 out of 5 (star star star)
Outperform Votes:  325 (Vote Outperform)
Underperform Votes:  106 (Vote Underperform)
Total Votes:  431
MarketBeat's community ratings are surveys of what our community members think about TG Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for TG Therapeutics (NASDAQ:TGTX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 9 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $26.75 (217.51% upside)
Consensus Price Target History for TG Therapeutics (NASDAQ:TGTX)
Price Target History for TG Therapeutics (NASDAQ:TGTX)
Analysts' Ratings History for TG Therapeutics (NASDAQ:TGTX)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/3/2017SunTrust Banks, Inc.Reiterated RatingBuy$28.00MediumView Rating Details
6/17/2017FBR & CoReiterated RatingBuyLowView Rating Details
6/5/2017Jefferies Group LLCReiterated RatingBuy$23.00MediumView Rating Details
4/21/2017Raymond James Financial, Inc.Reiterated RatingBuyHighView Rating Details
3/8/2017Ladenburg Thalmann Financial ServicesSet Price TargetBuy$30.00LowView Rating Details
3/7/2017HC WainwrightReiterated RatingBuy$18.00N/AView Rating Details
3/7/2017Langenberg & CompanyBoost Price TargetPositive$28.00 -> $30.00N/AView Rating Details
2/22/2017AegisInitiated CoverageBuy$26.00N/AView Rating Details
12/7/2016Roth CapitalSet Price TargetBuy$33.00N/AView Rating Details
10/6/2016Brean CapitalReiterated RatingBuy$28.00N/AView Rating Details
8/24/2016S&P Equity ResearchLower Price Target$7.15 -> $6.40N/AView Rating Details
(Data available from 10/18/2015 forward)

Earnings

Earnings History for TG Therapeutics (NASDAQ:TGTX)
Earnings by Quarter for TG Therapeutics (NASDAQ:TGTX)
Earnings History by Quarter for TG Therapeutics (NASDAQ TGTX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/9/2017Q2 2017($0.46)($0.45)$0.04 million$0.04 millionViewListenView Earnings Details
5/5/2017Q1 2017($0.42)($0.52)$0.04 million$0.04 millionViewN/AView Earnings Details
11/7/2016Q3($0.31)($0.50)$0.04 million$0.04 millionViewListenView Earnings Details
8/8/2016Q2($0.29)($0.33)$0.04 million$0.04 millionViewN/AView Earnings Details
5/10/2016Q1($0.36)($0.28)$0.04 million$0.04 millionViewListenView Earnings Details
3/7/2016Q4($0.32)($0.37)$38.10 million$38.10 millionViewN/AView Earnings Details
11/9/2015Q3($0.34)($0.28)$0.04 million$0.04 millionViewN/AView Earnings Details
8/10/2015Q215($0.32)($0.38)$0.22 million$0.04 millionViewListenView Earnings Details
5/4/2015Q115($0.33)($0.39)$0.04 million$0.04 millionViewN/AView Earnings Details
3/11/2015Q414($0.26)($0.48)$0.04 million$0.04 millionViewN/AView Earnings Details
11/10/2014Q214($0.32)($0.51)$0.04 million$0.04 millionViewN/AView Earnings Details
7/21/2014($0.28)($0.36)$0.04 million$0.04 millionViewN/AView Earnings Details
5/12/2014Q114($0.19)($0.25)$0.04 million$0.04 millionViewN/AView Earnings Details
3/5/2014Q413($0.18)($0.19)$40.00 million$38.10 millionViewN/AView Earnings Details
11/11/2013Q313($0.22)($0.62)$0.03 million$0.04 millionViewN/AView Earnings Details
8/1/2013Q213($0.16)($0.29)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for TG Therapeutics (NASDAQ:TGTX)
2017 EPS Consensus Estimate: ($1.82)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.48)($0.47)($0.48)
Q2 20173($0.45)($0.37)($0.41)
Q3 20173($0.50)($0.40)($0.45)
Q4 20173($0.54)($0.43)($0.48)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for TG Therapeutics (NASDAQ:TGTX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for TG Therapeutics (NASDAQ:TGTX)
Insider Ownership Percentage: 16.70%
Institutional Ownership Percentage: 49.86%
Insider Trades by Quarter for TG Therapeutics (NASDAQ:TGTX)
Institutional Ownership by Quarter for TG Therapeutics (NASDAQ:TGTX)
Insider Trades by Quarter for TG Therapeutics (NASDAQ:TGTX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/19/2017Sean A PowerCFOSell59,976$11.09$665,133.84View SEC Filing  
4/11/2017William James KennedyDirectorSell8,548$10.27$87,787.96View SEC Filing  
4/4/2017Laurence N. CharneyDirectorSell7,000$11.17$78,190.00View SEC Filing  
1/4/2017Sean A. PowerCFOSell8,816$4.55$40,112.80View SEC Filing  
4/18/2016Sean A PowerCFOSell10,000$10.12$101,200.00View SEC Filing  
1/5/2016Sean A PowerCFOSell22,790$11.21$255,475.90View SEC Filing  
7/8/2015William James KennedyDirectorSell17,000$17.08$290,360.00View SEC Filing  
7/1/2015Sean A PowerCFOSell50,054$16.46$823,888.84View SEC Filing  
4/2/2015Sean A PowerCFOSell23,800$15.50$368,900.00View SEC Filing  
1/7/2015Sean A PowerCFOSell66,401$16.40$1,088,976.40View SEC Filing  
1/5/2015Sean A PowerCFOSell54,057$16.40$886,534.80View SEC Filing  
12/16/2014Michael S WeissMajor ShareholderSell210,618$16.44$3,462,559.92View SEC Filing  
12/16/2014Sean A PowerCFOSell38,041$16.44$625,394.04View SEC Filing  
12/11/2013Michael Weissmajor shareholderBuy10,000$3.43$34,300.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for TG Therapeutics (NASDAQ:TGTX)
Latest Headlines for TG Therapeutics (NASDAQ:TGTX)
Source:
DateHeadline
finance.yahoo.com logoTG Therapeutics Announces Completion of Full Enrollment in the UNITY-CLL Phase 3 Trial
finance.yahoo.com - October 17 at 8:00 AM
finance.yahoo.com logoTG Therapeutics Provides Update on FDA Meeting for GENUINE Phase 3 Trial
finance.yahoo.com - October 17 at 8:00 AM
finance.yahoo.com logoTG Therapeutics, Inc. Recaps Clinical Data Presentations at the Upcoming 7th Joint ECTRIMS – ACTRIMS Meeting
finance.yahoo.com - October 17 at 8:00 AM
americanbankingnews.com logoTG Therapeutics, Inc. (TGTX) Cut to "Sell" at ValuEngine
www.americanbankingnews.com - October 16 at 10:36 PM
finance.yahoo.com logoTG Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : TGTX-US : October 12, 2017
finance.yahoo.com - October 13 at 9:17 AM
prnewswire.com logoBiotech Stock Performance Review -- Cyclacel Pharma, TG Therapeutics, Vericel, and Achaogen - PR Newswire (press release)
www.prnewswire.com - October 9 at 8:19 AM
globenewswire.com logoTG Therapeutics, Inc. Announces Advancement of its Anti-PD-L1 Monoclonal Antibody into Clinical Development - GlobeNewswire (press release)
globenewswire.com - October 6 at 3:38 PM
finance.yahoo.com logoTG Therapeutics, Inc. Announces Advancement of its Anti-PD-L1 Monoclonal Antibody into Clinical Development
finance.yahoo.com - October 6 at 11:17 AM
finance.yahoo.com logoTG Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : TGTX-US : September 27, 2017
finance.yahoo.com - October 3 at 1:30 PM
finance.yahoo.com logoTG Therapeutics, Inc. – Value Analysis (NASDAQ:TGTX) : September 28, 2017
finance.yahoo.com - October 3 at 1:30 PM
finance.yahoo.com logoTG Therapeutics Announces TGR-1202 (umbralisib) Selected For Grant from the National Multiple Sclerosis Society to Support the Development of TGR-1202 as an Oral B-cell Targeted Treatment Option in Progressive Multiple Sclerosis (PMS)
finance.yahoo.com - October 3 at 1:30 PM
finance.yahoo.com logoWhy You Need To Look At This Factor Before Buying TG Therapeutics Inc (TGTX)
finance.yahoo.com - October 3 at 1:30 PM
americanbankingnews.com logoTG Therapeutics, Inc. (TGTX) Expected to Post Earnings of -$0.46 Per Share
www.americanbankingnews.com - October 1 at 10:26 PM
streetinsider.com logoUPDATE: TG Therapeutics (TGTX) Secures Grant from National Multiple Sclerosis Society to Support Development of ... - StreetInsider.com
www.streetinsider.com - September 30 at 2:11 PM
seekingalpha.com logoTG Therapeutics (TGTX) Presents At Ladenburg Thalmann 2017 Healthcare Conference - Slideshow
seekingalpha.com - September 28 at 5:32 AM
americanbankingnews.com logoTG Therapeutics, Inc. (TGTX) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - September 23 at 8:50 PM
finance.yahoo.com logoTG Therapeutics, Inc. to Present at Upcoming Investor Conferences
finance.yahoo.com - September 23 at 10:00 AM
streetinsider.com logoTG Therapeutics (TGTX) Says Phase 3 ULTIMATE Trials Evaluating TG-1101 in Patients with RMS Are Now Open for ... - StreetInsider.com
www.streetinsider.com - September 16 at 9:26 AM
finance.yahoo.com logoTG Therapeutics, Inc. Announces the Phase 3 ULTIMATE Trials Evaluating TG-1101 in Patients with Multiple Sclerosis Are Now Open for Enrollment
finance.yahoo.com - September 15 at 9:53 AM
americanbankingnews.com logoTG Therapeutics, Inc. (TGTX) Short Interest Update
www.americanbankingnews.com - September 15 at 1:02 AM
finance.yahoo.com logoShould You Buy TG Therapeutics Inc (TGTX) Now?
finance.yahoo.com - September 14 at 11:17 AM
streetinsider.com logoTG Therapeutics (TGTX) Completes Enrollment in UNITY-CLL Phase 3 Trial
www.streetinsider.com - September 6 at 9:07 AM
finance.yahoo.com logoTG Therapeutics Announces Completion of Target Enrollment in the UNITY-CLL Phase 3 Trial
finance.yahoo.com - September 5 at 9:09 AM
streetinsider.com logoTG Therapeutics (TGTX) Plans Data Presentations at Joint ECTRIMS - ACTRIMS Meeting
www.streetinsider.com - September 2 at 9:32 AM
finance.yahoo.com logoETFs with exposure to TG Therapeutics, Inc. : September 1, 2017
finance.yahoo.com - September 1 at 9:44 AM
finance.yahoo.com logoTG Therapeutics, Inc. Announces Clinical Data Presentations at the Upcoming 7th Joint ECTRIMS – ACTRIMS Meeting
finance.yahoo.com - September 1 at 9:44 AM
americanbankingnews.com logoTG Therapeutics Inc (TGTX) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - August 29 at 9:14 PM
americanbankingnews.com logoTG Therapeutics, Inc. (TGTX) Expected to Announce Quarterly Sales of $40,000.00
www.americanbankingnews.com - August 27 at 3:58 AM
americanbankingnews.com logo Brokerages Anticipate TG Therapeutics, Inc. (TGTX) to Announce -$0.46 Earnings Per Share
www.americanbankingnews.com - August 25 at 4:28 PM
finance.yahoo.com logoTG Therapeutics, Inc. :TGTX-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
finance.yahoo.com - August 24 at 2:30 PM
finance.yahoo.com logoTG Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : TGTX-US : August 14, 2017
finance.yahoo.com - August 15 at 7:38 AM
americanbankingnews.com logoTG Therapeutics, Inc. to Post Q3 2017 Earnings of ($0.50) Per Share, Jefferies Group Forecasts (NASDAQ:TGTX)
www.americanbankingnews.com - August 14 at 1:24 AM
americanbankingnews.com logoQ3 2017 Earnings Estimate for TG Therapeutics, Inc. (NASDAQ:TGTX) Issued By SunTrust Banks
www.americanbankingnews.com - August 11 at 11:40 AM
streetinsider.com logoTG Therapeutics (TGTX) Reports Positive Outcome from First Interim Analysis by Independent DSMB of DLBCL Cohort in UNITY-NHL Phase 2b Trial
www.streetinsider.com - August 11 at 2:37 AM
americanbankingnews.com logoTG Therapeutics, Inc. (NASDAQ:TGTX) Issues Quarterly Earnings Results, Beats Expectations By $0.01 EPS
www.americanbankingnews.com - August 10 at 10:24 PM
streetinsider.com logoTG Therapeutics (TGTX) Reports Positive Outcome from First Interim Analysis by Independent DSMB of DLBCL Cohort ... - StreetInsider.com
www.streetinsider.com - August 10 at 9:34 PM
globenewswire.com logoTG Therapeutics, Inc. Announces Successful Outcome from the First Pre-Planned Interim Analysis by Independent ... - GlobeNewswire (press release)
globenewswire.com - August 10 at 8:41 AM
finance.yahoo.com logoEdited Transcript of TGTX earnings conference call or presentation 9-Aug-17 12:30pm GMT
finance.yahoo.com - August 10 at 8:40 AM
finance.yahoo.com logoTG Therapeutics, Inc. Announces Successful Outcome from the First Pre-Planned Interim Analysis by Independent DSMB of the DLBCL Cohort in the UNITY-NHL Phase 2b Trial
finance.yahoo.com - August 10 at 8:40 AM
globenewswire.com logoTG Therapeutics, Inc. Provides Business Update and Reports Second Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - August 9 at 8:10 AM
finance.yahoo.com logoInvestor Network: TG Therapeutics, Inc. to Host Earnings Call
finance.yahoo.com - August 9 at 8:10 AM
finance.yahoo.com logoTG Therapeutics, Inc. Provides Business Update and Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 9 at 8:09 AM
finance.yahoo.com logoTG Therapeutics reports 2Q loss
finance.yahoo.com - August 9 at 8:09 AM
americanbankingnews.com logo$40,000.00 in Sales Expected for TG Therapeutics, Inc. (TGTX) This Quarter
www.americanbankingnews.com - August 9 at 7:44 AM
fool.com logoWhat's Behind TG Therapeutics Inc.'s 14.4% Rally in July? - Motley Fool
www.fool.com - August 8 at 7:27 AM
fool.com logoWhat's Behind TG Therapeutics Inc.'s 14.4% Rally in July?
www.fool.com - August 7 at 5:25 PM
americanbankingnews.com logoTG Therapeutics, Inc. (NASDAQ:TGTX) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - August 4 at 8:44 PM
finance.yahoo.com logoTG Therapeutics, Inc. – Value Analysis (NASDAQ:TGTX) : August 4, 2017
finance.yahoo.com - August 4 at 9:02 AM
finance.yahoo.com logoTG Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : TGTX-US : August 2, 2017
finance.yahoo.com - August 3 at 7:54 AM
americanbankingnews.com logoReviewing Heron Therapeutics (HRTX) & TG Therapeutics (NASDAQ:TGTX)
www.americanbankingnews.com - August 3 at 7:52 AM

Social

Chart

TG Therapeutics (TGTX) Chart for Wednesday, October, 18, 2017

This page was last updated on 10/18/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.